Loading...

FITC anti-mouse CD4 Antibody

Pricing & Availability
Clone
GK1.5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
GK1.5_FITC_102110
C57BL/6 mouse splenocytes were stained with CD4 (clone GK1.5) FITC (filled histogram) or rat IgG2b, κ FITC isotype control (open histogram).
  • GK1.5_FITC_102110
    C57BL/6 mouse splenocytes were stained with CD4 (clone GK1.5) FITC (filled histogram) or rat IgG2b, κ FITC isotype control (open histogram).
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
100405 50 µg 24€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100406 500 µg 80€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes, a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a coreceptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosin kinase, lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse CTL clone V4
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The CD4 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Additional reported applications (for the relevant formats) include: blocking of CD4+ T cell activation1,4,11, thymocyte costimulation3, in vitro and in vivo depletion2,5-8, blocking of egg-sperm cell adhesion1,4, immunohistochemical staining of acetone-fixed frozen sections9,10, immunoprecipitation1,2, and spatial biology (IBEX)12,13. The GK1.5 antibody is able to block CD4 mediated cell adhesion and T cell activation. Binding of GK1.5 antibody to CD4 T cells can be blocked by RM4-5 antibody, but not RM4-4 antibody. For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100442) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).

Application References
  1. Dialynas DP, et al. 1983. J. Immunol. 131:2445. (Block, IP)
  2. Dialynas DP, et al. 1983. Immunol. Rev. 74:29. (IP, Deplete)
  3. Wu L, et al. 1991. J. Exp. Med. 174:1617. (Costim)
  4. Godfrey DI, et al. 1994. J. Immunol. 152:4783. (Block)
  5. Gavett SH, et al. 1994. Am. J. Respir. Cell. Mol. Biol. 10:587. (Deplete)
  6. Schuyler M, et al. 1994. Am. J. Respir. Crit. Care Med. 149:1286. (Deplete)
  7. Ghobrial RR, et al. 1989. Clin. Immunol. Immunopathol. 52:486. (Deplete)
  8. Israelski DM, et al. 1989. J. Immunol. 142:954. (Deplete)
  9. Zheng B, et al. 1996. J. Exp. Med. 184:1083. (IHC)
  10. Frei K, et al. 1997. J. Exp. Med. 185:2177. (IHC)
  11. Felix NJ, et al. 2007. Nat. Immunol. 8:388. (Block)
  12. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  13. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Zhao J, et al. 2021. Emerg Microbes Infect. 10:913. PubMed
  2. Liu J, et al. 2021. Front Immunol. 12:747730. PubMed
  3. Su Y, et al. 2022. J Hematol Oncol. 15:99. PubMed
  4. Xue G, et al. 2021. Cancer Cell. 39:1610. PubMed
  5. Mills EL, et al. 2022. Cell Metab. 34:140. PubMed
  6. Li X, et al. 2022. J Clin Invest. 132: . PubMed
  7. Wu R, et al. 2022. J Dermatol. 49:432. PubMed
  8. Mi Z, et al. 2021. Vaccines (Basel). 10: . PubMed
  9. Corral D, et al. 2022. Cell Rep. 39:110715. PubMed
  10. Lu R, et al. 2022. Scand J Immunol. 96:e13177. PubMed
  11. Shen Z, et al. 2022. EBioMedicine. 85:104285. PubMed
  12. Balood M, et al. 2022. Nature. 611:405. PubMed
  13. Zhu M, et al. 2022. Front Immunol. 13:1019248. PubMed
  14. Zhang Z, et al. 2022. Integr Cancer Ther. 21:15347354221138534. PubMed
  15. Wei M, et al. 2022. Front Immunol. 13:1017574. PubMed
  16. Wang H, et al. 2022. J Nanobiotechnology. 20:513. PubMed
  17. Chen C, et al. 2022. J Neuroinflammation. 19:315. PubMed
  18. Qin S, et al. 2023. Acta Pharm Sin B. :. PubMed
  19. Merk VM, et al. 2023. Genes Immun. 24:52. PubMed
  20. Meng S, et al. 2023. Stem Cell Investig. 10:2. PubMed
  21. Sun Y, et al. 2023. Cell Mol Life Sci. 80:63. PubMed
  22. Hajjar S, et al. 2022. Cell Death Differ. 29:585. PubMed
  23. Sylvester MA, et al. 2022. Am J Physiol Renal Physiol. 322:F245. PubMed
  24. Zander R, et al. 2022. Immunity. 55:475. PubMed
  25. Li Z, et al. 2022. Nat Commun. 13:1845. PubMed
  26. Zelenka T, et al. 2022. Nat Commun. 13:6954. PubMed
  27. Chuang H, et al. 2014. Nat Commun. 5:4602. PubMed
  28. Chang YS, et al. 2020. Int J Mol Sci. 21:00. PubMed
  29. Djokić V, et al. 2019. Front Immunol. 9:2891. PubMed
  30. Katsumura KR, et al. 2018. Proc Natl Acad Sci U S A. 115:E10109. PubMed
  31. Valanparambil RM, et al. 2017. PLoS Pathog. 13:e1006647. PubMed
  32. Wang X, et al. 2019. Cell Res. 29:787. PubMed
  33. Qiu Z, et al. 2022. J Exp Med. 219:. PubMed
  34. Lin J, et al. 2022. Adv Sci (Weinh). 9:e2202633. PubMed
  35. Hamdi L, et al. 2022. Ann Clin Transl Neurol. 9:1792. PubMed
  36. Deák P, et al. 2022. Cell Rep. 41:111563. PubMed
  37. Zhu C, et al. 2022. Chemotherapy. 67:211. PubMed
  38. Pan Y, et al. 2023. Adv Sci (Weinh). 10:e2206792. PubMed
  39. Wilson NG, et al. 2023. iScience. 26:105991. PubMed
  40. Zhuang WR, et al. 2023. Nat Commun. 14:1675. PubMed
  41. Mackin S, et al. 2023. Nat Microbiol. 8:569. PubMed
  42. Shi Y, et al. 2023. Nat Commun. 14:1884. PubMed
  43. Liu H, et al. 2023. Breast Cancer Res. 25:43. PubMed
  44. Fu S, et al. 2023. Nat Commun. 14:2248. PubMed
  45. Fiedler T, et al. 2023. J Neuroinflammation. 20:100. PubMed
  46. Yu L, et al. 2023. Front Oncol. 13:1174713. PubMed
  47. Wang Y, et al. 2023. iScience. 26:106630. PubMed
  48. Vereertbrugghen A, et al. 2023. J Neuroinflammation. 20:120. PubMed
  49. Peymanfar Y, et al. 2023. Int J Mol Sci. 24:. PubMed
  50. Wang X, et al. 2023. Nat Commun. 14:3440. PubMed
  51. Yao RQ, et al. 2023. Mil Med Res. 10:27. PubMed
  52. Iwanami N, et al. 2023. Nat Commun. 14:3645. PubMed
  53. Solvay M, et al. 2023. J Immunother Cancer. 11:. PubMed
  54. Wang Z, et al. 2023. Sci Adv. 9:eabo4100. PubMed
  55. Yang Z, et al. 2022. J Immunother Cancer. 10:. PubMed
  56. Li Q, et al. 2022. Cell Rep. 40:111308. PubMed
  57. Schönberger K, et al. 2022. Cell Stem Cell. 29:131. PubMed
  58. He R, et al. 2021. J Immunol. 206:2353. PubMed
  59. Ma J, et al. 2020. Adv Sci (Weinh). 7:2000609. PubMed
  60. Fan L, et al. 2021. Cancers (Basel). 13:. PubMed
  61. Rosenkranz SC, et al. 2021. eLife. 10:00. PubMed
  62. Furuta Y, et al. 2017. PLoS One. 12(2):e0172509. PubMed
  63. Wu N, et al. 2020. Cell Rep. 30:1129. PubMed
  64. Alissafi T, et al. 2018. J Clin Invest. 128:3840. PubMed
  65. Yang F, et al. 2021. Front Microbiol. 11:512581. PubMed
  66. Luo R, et al. 2021. Theranostics. 11:117. PubMed
  67. Xu ZH, et al. 2021. Mediators Inflamm. 2021:8856326. PubMed
  68. Liang S, et al. 2022. Acta Pharm Sin B. 12:2494. PubMed
  69. Jiang W, et al. 2022. Front Immunol. 13:878832. PubMed
  70. Toomer G, et al. 2022. Viruses. 14:. PubMed
  71. Sega E, et al. 2008. Int J Radiat Oncol Biol Phys. 71:559. PubMed
  72. Lua Y, et al. 2012. Mol Immunol. 52:229. PubMed
  73. Zasłona Z, et al. 2014. J Immunol. 193:4245. PubMed
  74. Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed
  75. Saleh MM, et al. 2019. Cell Host Microbe. 25:756. PubMed
  76. Liang Q, et al. 2022. iScience. 25:104043. PubMed
  77. Mirshahi F, et al. 2022. Cell Rep. 38:110454. PubMed
  78. Bangs DJ, et al. 2022. Cell Rep. 38:110266. PubMed
  79. Jazowiecka-Rakus J, et al. 2021. Cancers (Basel). 13:. PubMed
  80. Chen J, et al. 2022. J Nanobiotechnology. 20:283. PubMed
  81. Wu M, et al. 2021. Nat Commun. 12:3500. PubMed
  82. Fu Y, et al. 2020. Mol Ther. 1214:28. PubMed
  83. Altshuler A, et al. 2021. Cell Stem Cell. 28(7):1248-1261.e8. PubMed
  84. Tang Y, et al. 2020. Front Immunol. 11:585918. PubMed
  85. Periasamy S, et al. 2017. Nat Commun. 8:15564. PubMed
  86. Pobezinskaya EL et al. 2019. Front Immunol. 1.079861111 . PubMed
  87. Choi H et al. 2019. Cell Rep. 27(3):806-819 . PubMed
  88. Aqel SI, et al. 2021. JCI Insight. 6:e142376. PubMed
  89. Hu D, et al. 2021. J Cell Mol Med. 25:2900. PubMed
  90. Shi S, et al. 2020. Clin Cancer Res. 26:5990. PubMed
  91. Wang Y, et al. 2022. Acta Pharm Sin B. 12:262. PubMed
  92. Zhou HF, et al. 2022. Front Pharmacol. 13:778755. PubMed
  93. Liang Z, et al. 2021. J Cell Physiol. 236:4725. PubMed
  94. Mardomi A, et al. 2021. J Cell Physiol. 236:6328. PubMed
  95. Xu F, et al. 2022. Cell Death Discov. 8:142. PubMed
  96. Guan H, et al. 2012. PLoS One. 7:e35650. PubMed
  97. D Kim, S Lee, H Jun 2016. Immunol Cell Biol. 10.1038/icb.2016.98. PubMed
  98. He C, et al. 2020. Clin Transl Med. 10:e39. PubMed
  99. Molina-Sanchez P, et al. 2020. Gastroenterology. 2203:159. PubMed
  100. Brooks JF, et al. 2020. Cytotherapy. 22:436. PubMed
  101. Qi X, et al. 2019. Nat Commun. 10:2141. PubMed
  102. Wu J, et al. 2020. Sci Adv. 6:eaba3458. PubMed
  103. Mauduit O, et al. 2022. Front Immunol. 13:1011125. PubMed
  104. Liu Y, et al. 2022. Nat Commun. 13:2665. PubMed
  105. Anastasiou M, et al. 2021. JCI Insight. 6:. PubMed
  106. Li H, et al. 2021. Nat Commun. 12:2773. PubMed
  107. Jiang S, et al. 2020. Scand J Immunol. e12867:91. PubMed
  108. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  109. White C, et al. 2014. J Immunol. 193:5933. PubMed
  110. Sarapulov AV, et al. 2020. Front Immunol. 11:599. PubMed
  111. Thomas S, et al. 2019. J Immunother Cancer. 7:214. PubMed
  112. Tritama E, et al. 2018. Hum Vaccin Immunother. 14:1524. PubMed
  113. Cheng K, et al. 2021. Nat Commun. 12:2041. PubMed
  114. Edwards CJ, et al. 2021. Br J Cancer. . PubMed
  115. Jing L, et al. 2022. Front Immunol. 13:864995. PubMed
  116. Feng H, et al. 2020. J Dermatol. 47:147. PubMed
  117. Ren HZ, et al. 2022. J Clin Transl Hepatol. 10:1138. PubMed
  118. Ma X, et al. 2021. Cell Metabolism. 33(5):1001-1012.e5. PubMed
  119. Zongyi Y, et al. 2017. PLoS One. 10.1371/journal.pone.0189617. PubMed
  120. Raineri D, et al. 2021. Biomedicines. 10:. PubMed
  121. He X, et al. 2021. Small. 17:e2007165. PubMed
  122. Katsinas N, et al. 2022. J Clin Med. 11:. PubMed
  123. He X, et al. 2021. Adv Sci (Weinh). 8:e2103023. PubMed
  124. Chen L, et al. 2021. Cell Death Differ. 28:1880. PubMed
  125. Wang Z, et al. 2020. J Clin Invest. 130:3717. PubMed
  126. Pedraza–Zamora CP, et al. 2017. Parasite Immunol. 39:4. PubMed
  127. Cheng B, et al. 2022. Cancer Commun (Lond). 42:17. PubMed
  128. Wang Z, et al. 2022. Nat Biomed Eng. 6:791. PubMed
  129. Guo P, et al. 2021. J Immunol. 207:408. PubMed
  130. Vigeland C, et al. 2016. PLoS One. 11: 0163288. PubMed
  131. Lu X, et al. 2016. Nat Commun. 7: 12719. PubMed
  132. Deng Z, et al. 2020. World J Gastrointest Oncol. 1091:12. PubMed
  133. Zhang W, et al. 2019. Oncol Lett. 17:815. PubMed
  134. Cervera–Carrascon V, et al. 2020. Oncoimmunology. 9:1761229. PubMed
  135. Paul S, et al. 2018. Appl Microbiol Biotechnol. 102:8895. PubMed
  136. Zhao X, et al. 2022. Nat Protoc. 17:2240. PubMed
  137. Zhou H, et al. 2022. Oncoimmunology. 11:2057892. PubMed
  138. He X, et al. 2022. Cancer Immunol Res. 10:314. PubMed
  139. Hum NR, et al. 2022. Front Oncol. 12:928474. PubMed
  140. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  141. Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed
  142. Zhang Y, et al. 2021. J Immunol Res. 2021:5599439. PubMed
  143. Volberding PJ, et al. 2021. Cell Reports. 35(8):109160. PubMed
  144. Knocke S, et al. 2016. Cell Rep. 17:2234-2246. PubMed
  145. Ahmari N, et al. 2016. Physiol Genomics. 48: 526 - 536. PubMed
  146. Ito C, et al. 2015. PLoS One. 10: e0140808. PubMed
  147. Dmitrieva‐Posocco O et al. 2019. Immunity. 50(1):166-180 . PubMed
  148. Kim JH, et al. 2019. Mol Med. 25:33. PubMed
  149. Niknam S, et al. 2018. Clin Cancer Res. 24:5735. PubMed
  150. Habib S, et al. 2018. Infect Immun. 86:e00019. PubMed
  151. Haas MS, et al. 2020. Mol Cancer Res. 19:717. PubMed
  152. Zhu Y, et al. 2021. EMBO J. 40:e105320. PubMed
  153. Wang Y, et al. 2021. Front Microbiol. 12:701566. PubMed
  154. Gebre MS, et al. 2022. NPJ Vaccines. 7:88. PubMed
  155. Yang B, et al. 2022. Bioengineered. 13:2685. PubMed
  156. Uddback I, et al. 2016. Sci Rep. 6:20137. PubMed
  157. Toomer K, et al. 2016. J Immunol. 196: 3665 - 3676. PubMed
  158. Faust HJ, et al. 2020. J Clin Invest. 130:5493. PubMed
  159. Kruta M, et al. 2021. Cell Stem Cell. :. PubMed
  160. Zhang H, et al. 2019. Mol Cell. 76:110. PubMed
  161. Sun H, et al. 2022. Front Immunol. 13:818017. PubMed
  162. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  163. Ding P, et al. 2022. Bone Res. 10:42. PubMed
  164. Lang V, et al. 2021. Elife. 10:. PubMed
  165. Peng L, et al. 2022. Cell Rep Med. 3:100634. PubMed
  166. Huang L, et al. 2021. Breast Cancer Res Treat. Online ahead of print. PubMed
  167. Lu J, et al. 2021. Cell Death Discov. 7:165. PubMed
  168. Han F, et al. 2020. Invest Ophthalmol Vis Sci. 61:24. PubMed
  169. Yan J, et al. 2020. Cell Rep. 107820:31. PubMed
  170. Shannon JP, et al. 2021. Immunity. 54(2):276-290.e5. PubMed
  171. Mencl S, et al. 2014. J Neuroimmunol. 274:125. PubMed
  172. Zhou J, et al. 2019. Nat Commun. 10:2427. PubMed
  173. Zhang Q, et al. 2021. Front Cell Dev Biol. 9:655552. PubMed
  174. Guo S, et al. 2021. Sci Rep. 11:23745. PubMed
  175. Ma K, et al. 2022. iScience. 25:104347. PubMed
  176. Li J, et al. 2022. Nat Commun. 13:4032. PubMed
  177. Gao X, et al. 2022. Front Immunol. 13:799331. PubMed
  178. Zeng Q, et al. 2022. iScience. 25:105151. PubMed
  179. Kmieciak M, et al. 2011. J Vis Exp. 47: 2381. PubMed
  180. Li Y, Kaneda T 2016. Sci Rep. 6: 25077. PubMed
  181. Timilshina M, et al. 2017. PLoS One. 10.1371/journal.pone.0168942. PubMed
  182. Wang X, et al. 2020. Nat Commun. 4.505555556. PubMed
  183. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  184. Subramanian K, et al. 2019. Nat Microbiol. 4:62. PubMed
  185. Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed
  186. Tao Z, et al. 2019. Clin Cancer Res. 25:1113. PubMed
  187. Li Z, et al. 2022. Nat Commun. 13:6321. PubMed
  188. He C, et al. 2022. Nat Commun. 13:5459. PubMed
  189. Takaku S, et al. 2022. Evid Based Complement Alternat Med. 2022:6122955. PubMed
  190. Zhang S, et al. 2022. Nat Commun. 13:4744. PubMed
  191. Yuan M, et al. 2022. Oxid Med Cell Longev. 2022:5479491. PubMed
  192. Li J, et al. 2020. Development. :. PubMed
  193. Shibuya M, et al. 2021. iScience. 24:103131. PubMed
  194. Nasarre P, et al. 2021. Cancers (Basel). 13: . PubMed
  195. Wang Y, et al. 2020. Virol Sin. 36:122. PubMed
  196. Liu Y, et al. 2020. Oncol Lett. 2369:20. PubMed
  197. Martomo SA, et al. 2021. Mol Cancer Ther. 1.074305556. PubMed
  198. Zan H, et al. 2017. Nat Commun. 8:14244. PubMed
  199. Kamata T, et al. 2020. Cell Reports. 31(12):107802. PubMed
  200. Ouyang S, et al. 2019. J Immunol. 202:1441. PubMed
  201. Reynolds CJ, et al. 2018. Sci Rep. 8:672. PubMed
  202. Zhang Q, et al. 2022. Commun Biol. 5:544. PubMed
  203. Jazowiecka-Rakus J, et al. 2020. Mol Ther Oncolytics. 18:335. PubMed
  204. Soria-Castro R, et al. 2020. Sci Rep. 10:17802. PubMed
  205. Chen H, et al. 2022. Front Pharmacol. 13:827520. PubMed
  206. Karanika S, et al. 2022. Front Immunol. 13:972266. PubMed
  207. Ligon MM, et al. 2020. Mucosal Immunol. 1.172222222. PubMed
  208. Da Mesquita S, et al. 2021. Science Advances. 7(21):. PubMed
  209. Wedekind MF, et al. 2021. iScience. 24(7):102759. PubMed
  210. Nechama M, et al. 2018. Nat Commun. 9:1603. PubMed
  211. Xia Y, et al. 2018. Cell. 175:1059. PubMed
  212. Liu YG, et al. 2019. FASEB J. 33:5018. PubMed
  213. Yao C, et al. 2018. Autophagy. 1.854861111. PubMed
  214. Pan L, et al. 2022. Front Immunol. 13:837497. PubMed
  215. Zheng Y, et al. 2022. J Immunol. 208:501. PubMed
  216. He X, et al. 2021. J Immunother Cancer. 9:. PubMed
  217. Zhou H, et al. 2021. Cell Death Discov. 7:332. PubMed
  218. Liu Y, et al. 2020. Cell Death Dis. 11:1062. PubMed
  219. Si J, et al. 2020. Cancer Cell. 38(4):551-566.e11. PubMed
  220. Khosravi N, et al. 2018. Cancer Immunol Res. 0.797222222. PubMed
  221. Kos S, et al. 2019. PLoS One. 14:e0217762. PubMed
  222. Ji L et al. 2019. Immunity. 51(2):272-284 . PubMed
  223. Habtetsion T et al. 2018. Cell metabolism. 28(2):228-242 . PubMed
  224. Coley WD et al. 2018. F1000Research. 2018 Mar 14 [revised 2018 Jan 1] 0.5125. PubMed
  225. Sun F, et al. 2022. Cell Death Dis. 13:181. PubMed
  226. Zhong C, et al. 2021. J Virol. 95:e0092521. PubMed
  227. Magee JA, et al. 2021. Stem Cell Reports. 16:20. PubMed
  228. Xu Y, et al. 2021. iScience. 24:103445. PubMed
  229. Zhou S, et al. 2021. Adv Funct Mater. 31:. PubMed
  230. Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed
  231. Sears SM, et al. 2022. Kidney360. 3:818. PubMed
  232. Bryan Hart, Sunhee Lee 2016. PLoS Negl Trop Dis. 10:e0005229. PubMed
  233. Blaszczak AM, et al. 2020. Immunometabolism. 2:00. PubMed
  234. Yang C, et al. 2020. Cell Host Microbe. 467:27. PubMed
  235. Golan K et al. 2018. Cell stem cell. 23(4):572-585 . PubMed
  236. Sivapatham S, et al. 2019. Front Immunol. 1.865277778. PubMed
  237. Zhao Y, et al. 2020. Front Immunol. 2.572222222. PubMed
  238. Nakao R, et al. 2022. NPJ Vaccines. 7:153. PubMed
  239. Wang Y, et al. 2022. Nat Commun. 13:1454. PubMed
  240. Barsoumian HB, et al. 2022. Cancers (Basel). 14:. PubMed
  241. Chen YL, et al. 2022. Front Neurosci. 16:876582. PubMed
  242. Li Z, et al. 2022. Evid Based Complement Alternat Med. 2022:7421265. PubMed
  243. Yue T, et al. 2022. Cell Death Differ. 29:218. PubMed
  244. Aguilera TA, et al. 2020. Clin Cancer Res. 26:2972. PubMed
  245. Simoni L, et al. 2020. Cell Rep. 33:108330. PubMed
  246. Hart B, et al. 2015. PLoS Negl Trop Dis. 9: 0004046. PubMed
  247. Ramanan D, et al. 2020. Cell. 181(6):1276-1290. PubMed
  248. Hidalgo San Jose L, et al. 2020. Cell Rep. 30:69. PubMed
  249. Blaszczak AM, et al. 2019. J Immunol. 202:2451. PubMed
  250. Liang Z, et al. 2017. Autophagy. 14:505. PubMed
  251. Hsu HP, et al. 2021. J Biol Chem. 296:100419. PubMed
  252. Zhang M, et al. 2022. iScience. 25:104490. PubMed
  253. Chen Y, et al. 2021. Braz J Med Biol Res. 54:e9570. PubMed
  254. Rodrigues KA, et al. 2021. Sci Adv. 7:eabj6538. PubMed
  255. Kathania M, et al. 2022. Cell Rep. 40:111345. PubMed
  256. Gawish R, et al. 2022. Elife. 11:. PubMed
  257. Li J, et al. 2022. Nat Commun. 13:1481. PubMed
  258. Angela M, et al. 2016. Nat Commun. 7:13683. PubMed
  259. Gardenier J, et al. 2017. Nat Commun. 8:14345. PubMed
  260. Jaeger N, et al. 2020. Cell Rep. 33:108331. PubMed
  261. Zeng A, et al. 2020. Oncol Rep. . PubMed
  262. Bartley A, et al. 2018. Front Physiol. 9:1593. PubMed
  263. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  264. Hong Y, et al. 2019. J Extracell Vesicles. 8:1670893. PubMed
  265. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
  266. Liang Z, et al. 2022. iScience. 25:105233. PubMed
  267. Lestari SR, et al. 2020. J Ayurveda Integr Med. 11:414. PubMed
  268. Jiang W, et al. 2021. Cell Rep. 37:110112. PubMed
  269. Chang MH, et al. 2021. Cell Rep. 37:109902. PubMed
  270. Ding X, et al. 2021. Front Immunol. 12:667136. PubMed
  271. Guo S, et al. 2021. Frontiers in Immunology. 11:614667. PubMed
  272. Cortez MA, et al. 2020. Nat Commun. 3.819444444. PubMed
  273. Zhou T, et al. 2018. Mol Med Rep. 17:4883. PubMed
RRID
AB_312690 (BioLegend Cat. No. 100405)
AB_312690 (BioLegend Cat. No. 100406)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD4
Specificity Alt (DOES NOT SHOW ON TDS):
CD4
App Abbreviation (DOES NOT SHOW ON TDS):
FC,IHC-F,ICC
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.

Other Formats

View All CD4 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD4 GK1.5 FC
Biotin anti-mouse CD4 GK1.5 FC,IHC-F,ICC
FITC anti-mouse CD4 GK1.5 FC,IHC-F,ICC
PE anti-mouse CD4 GK1.5 FC
PE/Cyanine5 anti-mouse CD4 GK1.5 FC
Purified anti-mouse CD4 GK1.5 FC,IHC-F,ICC,IP,Costim,Block,Depletion
PE/Cyanine7 anti-mouse CD4 GK1.5 FC
APC/Cyanine7 anti-mouse CD4 GK1.5 FC
Alexa Fluor® 647 anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Alexa Fluor® 488 anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Pacific Blue™ anti-mouse CD4 GK1.5 FC
Alexa Fluor® 700 anti-mouse CD4 GK1.5 FC
PerCP anti-mouse CD4 GK1.5 FC
PerCP/Cyanine5.5 anti-mouse CD4 GK1.5 FC
Brilliant Violet 421™ anti-mouse CD4 GK1.5 FC,ICC,IHC-F
Ultra-LEAF™ Purified anti-mouse CD4 GK1.5 FC,Block,Costim,Depletion,IHC,IP
Alexa Fluor® 594 anti-mouse CD4 GK1.5 IHC-F,FC,ICC,SB
Brilliant Violet 711™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 510™ anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Brilliant Violet 605™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 785™ anti-mouse CD4 GK1.5 FC
PE/Dazzle™ 594 anti-mouse CD4 GK1.5 FC
APC/Fire™ 750 anti-mouse CD4 GK1.5 FC
GoInVivo™ Purified anti-mouse CD4 GK1.5 FC
Brilliant Violet 750™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 650™ anti-mouse CD4 GK1.5 FC
Spark Blue™ 550 anti-mouse CD4 GK1.5 FC
Spark NIR™ 685 anti-mouse CD4 GK1.5 FC
KIRAVIA Blue 520™ anti-mouse CD4 GK1.5 FC
PE/Fire™ 640 anti-mouse CD4 GK1.5 FC
APC/Fire™ 810 anti-mouse CD4 GK1.5 FC
PE/Fire™ 700 anti-mouse CD4 GK1.5 FC
Spark Violet™ 538 anti-mouse CD4 GK1.5 FC
Spark YG™ 593 anti-mouse CD4 GK1.5 FC
Spark Blue™ 574 anti-mouse CD4 Antibody GK1.5 FC
Spark UV™ 387 anti-mouse CD4 GK1.5 FC
Spark Blue™ 515 anti-mouse CD4 GK1.5 FC
Spark PLUS UV395™ anti-mouse CD4 GK1.5 FC
Spark Red™ 718 anti-mouse CD4 (Flexi-Fluor™) GK1.5 FC
Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account